Prolonged chylothorax is a rare, life-threatening, pleural effusion that may be encountered in the setting of trauma. Conservative treatment may be successful and is the traditional approach in cases of limited chyle output. Early surgical intervention is required in cases with large refractory chyle output, but may be associated with substantial morbidity and mortality. Percutaneous thoracic duct embolization is an uncommon, minimally invasive, safe and effective treatment alternative. We report a case of successful thoracic duct embolization to treat large-volume chylothorax due to blunt trauma.
Introduction
High output (> 1 liter per day) chylothorax is a life-threatening pleural effusion. Postsurgical chylothorax occurs in less than 0.5% of general thoracic surgical procedures. 1 Disruption of the thoracic duct due to blunt trauma is exceedingly rare. Chylothorax can quickly lead to dangerous hypovolemia, electrolyte abnormalities, malnutrition and immune compromise, 2,3 while the median time interval from the causative surgery or trauma to diagnosis of chylothorax is 7 days. 4 Conservative treatment aims at spontaneous closure of the chyle leak and consists of nutritional support, while chyle production is decreasing, and removal of the pleural fluid. Since this approach was introduced, the mortality due to post-traumatic chylothorax has declined from over 50% decades ago to about 10% in the late 20th century. 5 However, conservative treatment is effective in less than a half of all cases of chylothorax 1,2 and only seldom so in cases of high chylous output (> 1.5 liters per day). In these cases, thoracotomy and surgical ligation are required and can be associated with substantial morbidity and mortality.
However, in 1998, a new method of treatment of chyle leakage through percutaneous thoracic duct catheterization was reported by Cope 6 and a few larger series have been reported since. [7] [8] [9] This method provides a safe and effective alternative to the traditional management of high-volume chylothorax. However, the procedure is still rarely performed. We report a case of successful thoracic duct embolization (TDE) for large-volume chylothorax following blunt trauma.
Case report
A 26-year-old woman, a professional water skier, sustained a fall during practice at speeds in excess of 40 mph (65 km/h). She immediately developed sharp pleuritic chest pain limiting respiration, greater on the right than on the left, which subsequently subsided. Initially no treatment was sought, but she presented to an outside hospital for worsening pain 2 days later. At that time the chest pain was centrally located, described as pressure sensation. Her blood count was noted for leukocytosis of 17.2. Infectious work-up, including bacterial cultures and immunological studies, was completely unrevealing. A transthoracic echocardiogram was normal. A CT scan of the chest revealed no lymphadenopathy, but a large bilateral pleural effusion was visualized. Thoracentesis yielded 1500 ml of milky fluid with triglycerides of 1481 mg/dl. Cytology was benign with negative cultures. Chylothorax was diagnosed and total parenteral nutrition was initiated. However,
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pleural effusions were unremitting and daily large-volume thoracentesis had to be repeated for the next 5 days. Following the patient's transfer to our clinic, a repeat CT scan demonstrated a slightly dilated cisterna chyli and fluid collection in the middle mediastinum.
A lymphangiogram was performed similarly to the previously described technique. 8, 10 Briefly, methylene blue was injected subcutaneously in the web-spaces between the first three toes of the right foot in the pre-operative recovery room. Allowing adequate time for the dye to travel into the lymphatics of the foot (approximately 10-30 minutes), the patient was transferred to the interventional radiology suite. Bupivacaine (Hospira, Inc., Lake Forest, IL, USA) was used to anesthetize the dorsum of the foot and a 1-cm incision was made overlying a visible lymphatic. Using blunt dissection, a lymphatic was isolated and cannulated with a 30-gauge lymphatic needle (Cook, Bloomington, IN, USA). The needle was secured with 4-0 silk suture and hand injection of lipiodol (Guerbet, Roissy, France) confirmed no leakage. Injection of 10 ml of lipiodol was then performed using a lymphatic pump (Hyperion/Cordis, Miami, FL, USA) at 0.1 ml/min titrated up to 0.5 ml/min while confirming the absence of a lymphatic leak. Intermittent fluoroscopy was performed for the following few hours in the angiography suite while the contrast ascended normally up the lower extremity and abdomen until the cisterna chyli was visualized at T12/L1. Thoracic duct embolization was then performed. The upper abdomen was prepped and draped in a sterile fashion.
Ultrasound was used to plan the transhepatic approach, avoiding the bowel, gallbladder, and major veins. A 22-gauge, 20-cm Chiba needle (Remington Medical Inc., Alpharetta, GA, USA) was inserted into the cisterna chyli under fluoroscopic guidance using a bulls-eye approach in the right anterior oblique (RAO) and slightly caudal to cranial orientation. A Nitrex wire (ev3 Endovascular, Inc., Plymouth, MN, USA) was advanced into the thoracic duct and a 3-Fr dilator was advanced into the lower portion. Omnipaque 300 (GE Healthcare, Princeton, NJ, USA) was injected and digital subtraction angiography was performed showing a transected thoracic duct at the T8-9 level ( Figures  1 and 2) . The 3-Fr dilator was exchanged for a TurboTracker microcatheter (Boston Scientific, Natick, MA, USA), which along with a 0.018-inch GoldGlide wire (Terumo, Somerset, NJ, USA) were used to traverse the transection and to canulate the thoracic duct in the upper chest ( Figure  3 ). Ten 3-and 4-mm Nester coils (Cook, Bloomington, IN, USA) were deployed above, across, and below the transection. The TurboTracker was then exchanged for a Rebar microcatheter (ev3 Neurovascular, Irvine, CA, USA), a requirement for use of DMSO, and 1 ml of Onyx-34 glue (ev3 Endovascular, Inc.) was injected into the inferior thoracic duct above the level of cisterna while slowly pulling the catheter back into the cisterna. The thoracic duct was occluded ( Figure 4 ). The catheter was then removed and the incision in the foot sutured. The patient was discharged from the hospital after 4 days feeling well and with no signs of pleural fluid re-accumulation. At the latest follow-up 5 months later, her chest radiograph demonstrated no further pleural effusions and no abnormalities were reported on physical exam.
Discussion
Chylothorax is diagnosed by the presence of milky fluid during thoracentesis with a triglyceride content of greater than 110 mg/dl and a fluid cholesterol level lower than that of the blood. 11, 12 Conservative treatment is traditionally used for low-volume (< 1000 ml/dl) chylothorax; however, mortality remains high: up to 50% (10% after surgical repair). 13, 14 Iatrogenic chylothorax presents more commonly with unilateral (left 44%; right 43% ) than bilateral (13%) effusion. 8 Approximately half of all patients with chylothorax seen in a tertiary center are due to trauma or surgery. Malignancy accounts for 16.7% (lymphoma 11.3%). 4 The leading causes of surgical traumatic chylothorax include esophagectomy (28%), congenital heart disease surgery (28%), lung resection for cancer (6-27%), and coronary bypass surgery (9%). 4, 8 In absolute terms, esophagectomy is associated with the highest frequency of traumatic chylothorax: 3.9% vs 0.42% in general thoracic surgery. 1, 15 The traditional approach to chylothorax includes dietary modifications (with or without somatostatin use) and placement of chest tubes for up to 2 weeks. If unsuccessful, surgery is required and involves thoracotomy and ligation of the thoracic duct. When the duct identification is problematic, especially in malignancy and radiation fibrosis, pleurodesis and pleurectomy are used. 3 Percutaneous TDE, developed by Cope and Kaiser, 6,7 is a safe, low morbidity alternative to surgical interventions. It can be performed successfully in the majority (71%) of patients with highoutput chyle leaks, including cases of failed surgical ligation. In the largest series, no deaths were reported and the rate of complications was only 3% and included one case of asymptomatic embolization of the pulmonary artery with glue and two cases of leg edema and pedal suture dehiscence. 8 This is significantly lower than the mortality of 2.1% and morbidity of 38.3% in surgical cases. 1 Despite superior outcomes, TDE is a technically challenging procedure that is performed at very few centers. This expertise is rare and is an example of 'disappearing skills' because of a lack of familiarity with lymphangiography. In addition, dedicated lymphangiogram pumps are no longer manufactured and are extremely hard to acquire. 8 Our case is an example of a positive clinical outcome with no morbidity from TDE. It is in support of the new approach to treatment of chylothorax advocated by some other authors [7] [8] [9] 16 that considers TDE as a first-line option in patients with refractory chylous effusions. 
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